BCM
ACTU

BIOS Capital Management’s Actuate Therapeutics ACTU Stock Holding History

BIOS Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Hold
10,049,996
– – 36.9% 1
2026
Q1 		$27.5M Hold
10,049,996
– – 52.09% 1
2025
Q4 		$61.5M Hold
10,049,996
– – 74.44% 1
2025
Q3 		$67.2M Buy
10,049,996
+84,917
+0.9% +$616K 75.62% 1
2025
Q2 		$60.9M Buy
9,965,079
+71,428
+0.7% +$624K 83.89% 1
2025
Q1 		$67M Hold
9,893,651
– – 84.59% 1
2024
Q4 		$78.8M Buy
+9,893,651
New +$80.7M 83.69% 1

Other funds holding ACTU

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

BIOS Capital Management's ACTU Position: Q2 2026 in Review

BIOS Capital Management held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 10,049,996 shares worth $15.4M. The position accounts for 36.9% of the portfolio, ranked #1.

BIOS Capital Management first reported a position in ACTU in Q4 2024 and has held it in 7 quarters since. The position peaked at $78.8M in Q4 2024. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • BIOS Capital Management held 10,049,996 shares of Actuate Therapeutics worth $15.4M as of Q2 2026.
  • BIOS Capital Management left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up 36.9% of BIOS Capital Management's portfolio in Q2 2026, its #1 holding.
  • BIOS Capital Management first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BIOS Capital Management's Actuate Therapeutics position peaked at $78.8M in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on BIOS Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.